Adiponectin expression-inducing agents and uses thereof
US7741080B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 31, 2005 |
| Grant date | Jun 22, 2010 |
| Priority date | — |
| Expiry date | Jan 10, 2026 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/044
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents.KLF9, which can bind to the 32-bp fragment of position −188 to position −157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity. Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.